心不全患者の薬物不服を予測するリスクスコアの開発と検証
Tomoaki Ishida1,2, Kei Kawada3,4, Kohei Jobu1
1Department of Pharmacy, Kochi Medical School Hospital, Nankoku, Kochi 783-0043, Japan.
Biological & pharmaceutical bulletin
|February 18, 2026
まとめ
新しいリスクスコアにより,心不全の患者が退院後,薬剤に不従順になる可能性が高いことが判明しました. 高いスコアはより高い死亡率を予測し,より良い心不全管理のためのターゲットを絞った介入を可能にします.
科学分野:
- 心臓病学 心臓病学
- クリニカル・メディシン 臨床医学
- 医療サービス 研究 医療サービス
背景:
- 薬物不服従は,心不全 (HF) の管理における重要な問題である.
- 不服従のリスクが高い患者を特定することは,アウトカムを改善するために非常に重要です.
研究 の 目的:
- 病院入院時に不補償性心不全患者の薬物不服を予測するための臨床的に適用可能なリスクスコアを開発し,検証する.
主な方法:
- 795人のHF患者を対象に,前向きな多センターコホート研究が行われました.
- ロジスティック回帰により,非遵守の予測要因が特定され,リスクスコアが得られた.
- モデルの性能は,受信機の動作特性曲線 (AUC) の下の面積を使用して評価されました.
主要な成果:
- 薬物不服従による入院は,患者の6.4%で発生しました.
- 予測要因には,認知症,男性性,現在の喫煙,非補助的な生活,および以前のHF入院が含まれています.
- より高いリスクスコアは,2年間で全因および心血管疾患による死亡率の増加と相関していた (AUC = 0.704).
結論:
- 入院ベースのリスクスコアは,HF患者の薬物不服従のリスクを効果的に特定します.
- このスコアは,アデバーンスと長期のHFアウトカムを改善するためのターゲットを絞った介入を導くことができます.
- ルーティンケアへの統合は,退院後の合併症を軽減し,多分野計画を強化する可能性があります.
関連する概念動画
Heart Failure V: Medical Management
381
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
381
Heart Failure VII: Nursing Interventions
559
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
559
Heart Failure IV: Classification and Diagnostic Evaluation
453
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
453
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Heart Failure VI: Adjunct Therapies
417
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
417
Drug Toxicity: Risk factors
27
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27


